Key result
Ivabradine produces negligible reduction in dynamic LVOT obstruction versus atenolol in cats with preclinical HCM.
Why the study?
Does a single dose of ivabradine reduce dynamic left ventricular outflow tract obstruction compared to atenolol in cats with preclinical hypertrophic cardiomyopathy?
RCT (n=28)
Double-blind
Randomized
Does a single dose of ivabradine reduce dynamic left ventricular outflow tract obstruction compared to atenolol in cats with preclinical hypertrophic cardiomyopathy?
Absolute Event Rate: 0.32% vs 2.53%
p-value: p=<.0001
In cats with preclinical HCM, a single dose of ivabradine decreases dynamic LVOT obstruction, but the clinical effect is negligible and inferior to atenolol.
Negligible ivabradine effect on feline LVOT obstruction versus atenolol warrants veterinary caution; leaves open dose-finding studies in HCM models.
Background Ivabradine is a negative chronotropic drug with minimal effects on central hemodynamics. Its effect on dynamic obstruction of the left ventricular outflow tract (LVOT) in cats with hypertrophic cardiomyopathy (HCM) remains unknown. Hypothesis/Objectives Ivabradine reduces dynamic obstruction of the LVOT in cats with HCM. Animals Twenty-eight client-owned cats with preclinical HCM and dynamic LVOT obstruction. Methods Randomized, double-blind, active-control single dose study. Cats received a single dose of either ivabradine (0.3 mg/kg PO) or atenolol (2 mg/kg PO). Heart rate, echocardiographic variables, and systolic blood pressure (SBP) were recorded before and 3 hours after drug administration. Statistical comparisons were made using ANCOVA. Results Peak velocity in the LVOT was significantly decreased compared to baseline for both drugs; however, the effect was more prominent with atenolol (mean reduction 2.53 m/s; 95% CI 2.07–3.13 m/s) compared to ivabradine (mean reduction 0.32 m/s; 95% CI −0.04 to 0.71 m/s; P < .0001). Echocardiographic indices of systolic function were largely unchanged by ivabradine, but significantly reduced by atenolol. Conclusions and Clinical Importance A single dose of ivabradine decreases dynamic LVOT obstruction in cats with HCM, but the clinical effect is negligible and inferior compared to that achieved by atenolol.
No takes yet. Share an insight, caveat, or question.
Blass et al. (2014) conducted an RCT in Preclinical hypertrophic cardiomyopathy with dynamic LVOT obstruction in cats (n=28). Ivabradine vs. Atenolol (2 mg/kg PO single dose) was evaluated on Peak velocity in the left ventricular outflow tract (LVOT) (p=<.0001). A single dose of ivabradine produced a negligible reduction in dynamic LVOT obstruction compared to atenolol (mean reduction 0.32 m/s vs 2.53 m/s; P<.0001) in cats with preclinical HCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: